@Chrystaltrade
Roughly 95% of 'sales' are for taxpayer funded trials in Georgia and Colorado.
No Cost-Benefit analysis has ever been published.
Sales (aka subsidises) are <10% of the amount need to break even.
Not only EDE., page-11
Add EDE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.216M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| EDE (ASX) Chart |
Day chart unavailable